Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

Inclusion Criteria: * Aged between 18 and 50 years * HIV-1 type B infected but asymptomatic patient * Patient who has received HAART less than 6 months according to the standard management guidelines and reached to aviremia * Patient with appropriate immunity (i.e., CD4 counts\>=400cells/ul and SI\>3 by CD4+ T-cell proliferation in vitro assay) * Patient with negative HBV and HCV * Woman who is not childbearing or who has used any contraceptive at least for 3 months before study entry * Patients given a written consent Exclusion Criteria: * Patient who has received other investigational drug or who participated into other study within 30 days before this study * Patient who had an experience of hypersensitivity to same drug (for example: a plasmid DNA, etc) * Patient who has received an immunosuppressant * Patient who has received other HIV vaccine * Patient who has received other interleukin(s) * Patient who experienced an opportunistic infection defined as AIDS before this study * Patient with any severe recurrent diarrhea or vomiting * Patient with clinically significant acute or chronic liver dysfunction, kidney dysfunction, hematological disorder, endocrine disorder, immune disorder, heart disease, infection, etc. * Patient with malignant tumor(s) * Patient with alcohol or drug abuse * Patient of potential harm due to drug interactions by HAART * Woman of pregnancy (positive pregnancy test) or beast feeding * Patient who is not appropriate at investigator's discretion, not specified in above